allopregnanolone (SPT-300) — Topline data
in 2H 2026
Phase 1 driving simulation trial of GlyphAllo on track to report topline data in 2H 2026Source filing
SPTX biotech catalysts & pipeline
SEAPORT THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
allopregnanolone (SPT-300) — Topline data
in 1H 2027
Enrollment in Phase 2b BUOY-1 trial of GlyphAllo TM in major depressive disorder (MDD) is on track with topline data expected in 1H 2027Source filing
agomelatine (SPT-320) — Topline data
early 2028
Topline data from this trial are expected in early 2028.Source filing
GlyphAgo ("Glyph Agomelatine") — Topline data
early 2028
We plan to initiate a Phase 2a proof-of-pharmacology trial designed to evaluate the potential sleep benefit of GlyphAgo in patients with GAD and sleep disturbance, with topline data expected in early 2028 and, in parallel, a Phase 2b trial designed to evaluate the efficacy and safety of GlyphAgo in patients with GAD, with topline data expected by the end of 2028.Source filing
GlyphAgo TM (SPT-320 or Glyph Agomelatine) — Topline data
early 2028
Topline data from this trial are expected in early 2028.Source filing
agomelatine (SPT-320) — Topline data
Late 2028
Topline data from this trial are expected by year-end 2028.Source filing
GlyphAgo ("Glyph Agomelatine") — Topline data
Late 2028
We plan to initiate a Phase 2a proof-of-pharmacology trial designed to evaluate the potential sleep benefit of GlyphAgo in patients with GAD and sleep disturbance, with topline data expected in early 2028 and, in parallel, a Phase 2b trial designed to evaluate the efficacy and safety of GlyphAgo in patients with GAD, with topline data expected by the end of 2028.Source filing
GlyphAgo TM (SPT-320 or Glyph Agomelatine) — Topline data
Late 2028
Topline data from this trial are expected by year-end 2028.Source filing